Related Experiment Video
Updated: Mar 28, 2026
piggyBac Transposon System Modification of Primary Human T Cells
Published on: November 5, 2012
Development of an optimized cytotoxicity assay system for CYP3A4-mediated metabolic activation via modified piggyBac
Lizhen Huang1, Shuxiang Zou2, Jifeng Deng2
1School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China; Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou 510006, China.
Abstract:
Drug-induced hepatotoxicity is often caused by cytochrome P450 (CYP)-dependent metabolism of drugs into reactive metabolites. Assessment of hepatotoxicity induced by bioactive compounds is hampered by low CYP expression within in vitro cell lines. To overcome this limitation, piggyBac transposition and monoclonal expansion were used to generate a HepG2 cell line with stable and homogenously high expression of CYP3A4, a prominent CYP isoform. Our studies demonstrate the generated line's constant CYP3A4 expression and activity for over 40 cell passages; to date, it has been in subculture for more than a year without addition of Puromycin. This cell line was utilized to evaluate cytotoxicity of two bioactive (troglitazone and acetaminophen) and two non-bioactive (citrate and galactosamine) compounds by MTT assay. Cell viability significantly decreased upon treatment with bioactive drugs. Moreover, cell lines used in the present study were more sensitive to toxic effects of troglitazone than previously reported. Therefore, this HepG2 cell-based assay system may provide a suitable hepatic model for predicting CYP3A4-mediated hepatotoxicity during preclinical drug development.
Insights
Researchers developed a novel HepG2 cell line with high CYP3A4 expression to study drug-induced liver injury. This model accurately predicts hepatotoxicity from bioactive compounds, aiding preclinical drug development.
Area of Science:
- Pharmacology
- Hepatology
- Biotechnology
Background:
- Drug-induced hepatotoxicity is a significant concern in drug development, often linked to cytochrome P450 (CYP)-mediated metabolism.
- Existing in vitro models have limitations due to low CYP enzyme expression, hindering accurate toxicity assessments.
- Cytochrome P450 3A4 (CYP3A4) is a key enzyme in drug metabolism and a frequent mediator of drug-induced liver injury.
Purpose of the Study:
- To develop a robust in vitro model for assessing drug-induced hepatotoxicity.
- To generate a HepG2 cell line with stable, high-level expression of CYP3A4.
- To evaluate the utility of this engineered cell line in predicting the toxicity of known bioactive compounds.
Main Methods:
- Utilized piggyBac transposition and monoclonal expansion to create a HepG2 cell line with enhanced CYP3A4 expression.
- Maintained stable CYP3A4 expression and activity in the cell line for over 40 passages (>1 year).
- Assessed compound cytotoxicity using MTT assays on the engineered HepG2 cells treated with troglitazone, acetaminophen, citrate, and galactosamine.
Main Results:
- The engineered HepG2 cell line demonstrated consistent CYP3A4 expression and activity over extended culture periods.
- Treatment with bioactive compounds (troglitazone, acetaminophen) significantly reduced cell viability.
- The cell line exhibited heightened sensitivity to troglitazone's toxic effects compared to previous reports.
Conclusions:
- The developed HepG2 cell line provides a reliable in vitro model for studying CYP3A4-mediated drug metabolism and toxicity.
- This model system shows promise for predicting drug-induced hepatotoxicity during preclinical drug development.
- The enhanced sensitivity of this model may reveal toxicities not detected by conventional assays.
